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ABSTRACT 
DNA methylation is the principle epigenetic modification mediating cell-specific functional 
variation in the phenotypic expression of the genome. This phenomenon is essential for genome 
maintenance and chromosomal integrity. The main players in this scheme are the DNA 
methyltransferases DNMT1, DNMT3A, DNMT3B who faithfully replicate the pre-existing 
methyl marks and propagate the methylation patterns across successive cell generations. The 
DNMTs are supported in their function by the methyl binding domain proteins called MBD 
proteins. This family of proteins preferentially binds methylated CpG dinucleotides, hinder the 
interaction of transcription factors with the DNA and prevent assembling of the transcriptional 
mechanism, thus result in heterochromatinization and transcriptional silencing. The functional 
significance of the MBD proteins in the transcriptional regulatory system necessitates the need to 
understand the involvement of these proteins in the epigenetic context. Keeping this observation 
in mind, the present study was designed to investigate the expression pattern and gene profiling 
of MBD proteins (MBD1, MBD2, MBD3 and MBD4) so as to conduct a comparative analysis of 
their relative levels of expression in leukemia samples. The project aims to provide a 
comprehensive knowledge about the expression of the MBD proteins in cancer samples in order 
to create a distinct epigenetic biomarker for effective prognosis of cancer. Further studies in a 
variety of different cancer tissues will provide an exhaustive idea regarding the role of MBD 
proteins in malignant transformation and subsequently result in an epigenetic signature for 
efficient molecular detection strategies. 
 
Keywords: Epigenetics, DNA methylation, MBD proteins, Cancer, Leukemia. 
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INTRODUCTION 
Cancer is a process driven by the growth of abnormality in gene function; although many 
of these changes are genetic, epigenetic changes in gene expression are being progressively more 
appreciated. This process involves two components of heritable, but reversible, accent of gene 
promoter utility that are closely tied to one another – formation of chromatin which modulates 
transcription and establishing patterns of DNA methylation. Epigenetic modifications that affect 
gene expression include post-translational modifications on N-terminal tails of histones and 
DNA methylation. Detailed investigation of epigenetic status can provide insight into the 
position and function of genetic regulatory elements on a genome-wide origin .A major dispute 
in the post-genomic era is the mapping and functional characterization of the full balance of 
transcriptional regulatory elements as well as promoters and enhancers also locus control regions 
(LCRs) and chromatin domain frontier elements. Epigenetics, the cell-type-specific 
interpretation of genetic material, present on DNA methylation and post-translational histone 
modifications to control gene function.  
 DNA (cytosine-5) methylation is known to be an evolutionary process and affects lively 
chromatin formation (Patra, et al., 2001). The enzyme responsible for DNA methylation is DNA 
methyltransferase (DNMT). Many isoforms (i.e., DNMT 1, 2, 3a, 3b, and 3L) of human DNMT 
be now recognized and known to perform a specific pattern of methylation [T.H. Bestor, 2000]. 
DNA methylation is a vital for suitable chromatin structure and function in mammalian cells. 
DNA methylation is a quintessential process in cellular context helping in parental imprinting, 
transposon silencing, chromosome dosage compensation, and also genome stability. Aberrant 
hypermethylation of promoter CpG islands and the resulting transcriptional silencing is 
nowadays a widely accepted mechanism of inactivation of tumor suppressor genes in cancer that 
actively contributes to tumorigenesis (Jones and Laird, 1999; Herman and Baylin, 2003). One of 
the key achievements in cancer epigenetics has been the recognition of profiles of aberrant CpG 
hypermethylation that are specific to the tumor type (Costello, et al., 2000; Esteller, et al., 2001). 
The survival of these profiles provide a powerful set of markers for outlining the disruption of 
critical pathways in tumorigenesis and for deriving sensitive molecular detection strategies for 
virtually every human tumor category. The orderly study of DNA methylation patterns in human 
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cancer cell lines has shown that these are appropriate models for this type of study as they show 
methylation patterns that resemble their corresponding tumor types (Smiraglia, et al., 2001; Paz, 
et al., 2003).   
Classical methyl-CpG binding proteins contain the conserved DNA binding motif methyl 
cytosine binding domain (MBD),which preferentially bind to methylated CpG dinucleotides. 
These proteins provide as transcriptional repressors, mediating gene silencing by means of DNA 
cytosine methylation. Mutations within methyl-CpG binding protein 2(MeCP2) have been 
associated to the human mental retardation disorder Rett syndrome, suggesting an important 
function for methyl- CpG binding proteins in brain development and function.MeCP2 recruits 
histone modifying proteins which aid in the formation of the heterochromatin (inactive 
chromatin). An additional influence of methylated DNA on gene transcription is due to the 
hindrance offered by the methylated cytosine residue which interferes with transcription factor 
binding and assembling of the transcriptional mechanism (Takizawa, et al., 2001). 
DNA methylation is the major modification of eukaryotic genomes and plays an essential 
function in mammalian progression. Human proteins MECP2, MBD1, MBD2, MBD3 and 
MBD4 encompass a family of nuclear proteins related by the presence in each of a methyl-CpG 
binding domain (MBD). Each of these proteins, with the exemption of MBD3, is capable of 
binding specifically to methylated DNA. MECP2, MBD1 and MBD2 can in addition repress 
transcription from methylated gene promoters. In contrast to other MBD family members, 
MECP2 is X-linked and subject to X inactivation. MECP2 is not necessary in stem cells. MECP2 
gene mutations are the reason of most cases of Rett syndrome, a rapid neurologic developmental 
disorder and one of the most common causes of mental retardation in females. In the light of the 
functional significance of the MBD proteins in the epigenomic landscape, the present study was 
designed to investigate the expression pattern and gene profiling of this family of proteins 
(MBD1, MBD2, MBD3 and MBD4) so as to study their relative levels of expression in leukemia 
samples. The project aims to provide a comprehensive knowledge about the gene expression of 
the MBD proteins in cancer samples so as to create a distinct epigenetic biomarker for effective 
prognosis. Further studies in a variety of different cancer tissues will provide an exhaustive idea 
regarding the role of MBD proteins in malignant transformation and subsequently result in a 
epigenetic signature for efficient molecular detection strategies. 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
Epigenetics [ Epi-above/over/beyond; above genetics] is the study of heritable changes in 
gene expression or cellular phenotype caused by mechanisms other than changes in the 
underlying DNA sequence that result in cell specific functional variations in phenotype. It 
involves functionally significant modifications to the genome that does not include a change in 
the nucleotide chain. Examples of such changes are DNA methylation and Histone deacetylation, 
both of which suppress gene expression. Epigenetic variations in gene expression do not result in 
changes in the nucleotide sequence of DNA and consequently are not mutations. The study 
epigenesis which refers to hypothetical aspects of developmental biology and the strategy of 
genes was given by C.H.Waddington during 1930-1960.epigenetic modifications are heritable, 
reversible covalent modifications that work in tandem to orchestrate the transcriptional activity 
of the genome in various biological settings. These modifications include DNA methylation, 
Histone modifications and Non-coding RNA mediated gene regulation. Of these three, DNA 
methylation is the first and most extensively researched epigenetic manipulation.  
 
2.1. DNA Methylation:- 
 Cytosine methylation at the 5-carbon position is the only known constant base 
modification seen in the mammalian genome. The organization and modification of chromatin is 
a key feature in programming gene expression models. Recent discoveries suggest that DNA 
methylation at the junction of transcription beginning and elongation plays a critical role in 
suppression of transcription. This effect is mechanistically mediated by the state of chromatin 
modification. DNA methylation attracts binding of methyl- CpG-binding domain proteins that 
trigger repression of transcription, whereas DNA demethylation facilitates transcription 
activation. It is paradox that DNA is a very stable molecule whose structure is faithfully 
maintained from generation to generation, yet with each round of replication, this structure is 
modified by base methylation in nearly all cells and organisms. The consequences of this 
modification are obviously of vital concern for all biologists. As well as the four major bases, the 
DNA of most organisms contains one or more minor bases. The commonest of these is 5-
methylcytosine, but N-methyl adenine and N4-methylcytosine are also found, particularly in 
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prokaryotes. In vertebrates 3-6% of DNA cytosine is methylated, but this importance decreases 
going down the evolutionary extent so that in many insects and single-celled eukaryotes there is 
no noticeable 5-methylcytosine. In contrast, plants may have 3000 of their DNA cytosine 
methylated (Adams & Burdon, 1985).  
 
Fig 1: Epigenetic mechanisms are affected by several factors and processes  
(Adapted from Adams, R. L. P. & Burdon, R. H., Springer link, 1985). 
 
 DNA (cytosine-5-carbon) methylation is one of the hallmarks of mammalian chromatin 
modifications. Distinct methyl can generate synergistic or antagonistic interaction affinities 
before CpG-islands associated with methylated or unmethylated cytosine binding proteins, which 
may also dictate histone modification and dynamic transition between transcriptionally silent or 
transcriptionally active chromatin states (Patra et al,2008). In zygote development just after 
fertilization, parental DNA experiences drastic loss of DNA-methylation before the zygote starts 
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dividing (before its DNA is replicated).The enzyme and cofactors involved are still unknown. 
However the egg-derived DNA remains mostly methylated (Patra et al., 2008). 
 DNA methylation is the major modification of eukaryotic genomes and plays an essential 
role in mammalian development. Human proteins MECP2, MBD1, MBD2, MBD3, and MBD4 
comprise a family of nuclear proteins related by the presence in each of a methyl-CpG binding 
domain (MBD). Each of these proteins, with the exception of MBD3, is capable of binding 
specifically to methylated DNA. MECP2, MBD1 and MBD2 can also repress transcription from 
methylated gene promoters. Five transcript variants of the MBD1 are generated by alternative 
splicing resulting in protein isoforms that contain one MBD domain, two to three cysteine-rich 
(CXXC) domains, and some differences in the COOH terminus. All five transcript variants 
repress transcription from methylated promoters; in addition, variants with three CXXC domains 
also repress unmethylated promoter activity. MBD1 and MBD2 map very close to each other on 
chromosome 18q21. 
2.2. Methyl Binding Proteins:- 
 Eukaryotic chromosomes are the repositories of the genetic information necessary to 
direct the synthesis of cellular components. Information is embedded in them at multiple levels. 
In addition to the genetic information contained in the sequence of nucleotide bases, 
chromosomes contain an `epigenetic code' that provides information crucial to regulation of the 
DNA itself. One component of this results from a system that covalently modifies cytosine 
residues by methylation at the 5 position of the pyrimidine ring (Bestor, 1990; Bird and Wolffe, 
1999; Jaenisch and Bird, 2003). In almost all cases, mammalian DNA methylation occurs solely 
within the context of a simple palindromic sequence, CG, in which both cytosine residues are 
methylated. The methyl groups protrude into the major groove of DNA, providing novel 
functional moieties available for molecular interactions within this key surface of the double 
helix. The methylated fraction of the genome includes such interesting loci as imprinted genes, 
the inactive X chromosome, and transposable elements and their relics. These regions are 
strongly repressed and DNA methylation is believed to play an integral role in establishment 
and/or maintenance of this repression. 
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 Methylation-mediated gene regulation is proposed to occur through the following two 
mechanisms. Firstly, CpG methylation within the transcription factor binding domain may 
directly interfere with the binding of certain transcription activators to the target sequence (Watt 
and Molloy, 1998, Takizawa et al, 2001). More generally, methylation-mediated gene silencing 
is through the action of a family of methyl-CpG binding proteins such as MeCP2 and MBD1, 
which preferentially bind to methylated CpG(s) (Lewis, et al., 1992, Cross, et al, 1997, Nan, et 
al., 1997). 
  
At present, five proteins with mCpG-binding motifs have been identified in the MBD 
family, namely MBD1, MBD2, MBD3, MBD4 and MeCP2. All MBD proteins share a similar 
MBD of about 75 amino-acid residues. Sequence alignment of MBD proteins reveals several 
highly conserved residues on the interface between MBD and methylated DNA (mDNA). The 
conserved residues of the MBD form the interfacial surface contacting mDNA and are 
responsible for recognition of the methyl-CpG steps. 
 
 
Fig 2: Sequence alignment of five methyl-CpG binding domain (MBD) proteins from 
human and mouse (Adapted from Bestor, T. H, Biological science, 1990) 
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Methyl-CpG–DNA binding proteins MeCP2, MBD1, MBD2, MBD3, and MBD4 
comprise another distinct class of mammalian nuclear proteins (Ng, et al., 1999, Hendrich et al., 
1999). Among these, MeCP2 is capable of binding to a single, symmetrically methylated CpG 
dinucleotide and binds to chromosomes at sites known to contain methylated DNA. MBD1 is a 
transcriptional regulator characterized by two or three CXXC domains that bind methylated CpG 
islands of the tumor suppressors p16, VHL, and E-cadherin genes and repress transcription 
(Patra et al,2001) MBD2 has been reported to possess DNA (cytosine-5) demethylase activity 
(Bhattacharya et al.,1999) along with repressor function [31,35,36]. MBD4 is a repair enzyme of 
the DNA-glycosylase family (Zhu et al., 2000) and MBD3 apparently lacks specific methylated 
DNA-binding capability although it has a high degree of sequence similarity with MBD2 
(Hendrich et al,, Bhattacharya et al,, R.I.D et al., 1999). The finding that the hyper-methylation 
of promoters is associated with silencing of several genes in human prostate cancer is noted in 
the literature but the study of the respective enzymes and their relative levels, and repressor 
proteins is lacking. 
 Recently we have shown that DNMT1 and HDAC1 are up-regulated (Patra et al., 2001), 
and DNA demethylase activity and MBD2 protein expression are lacking (Patra et al.,2002)in 
human prostate cancer. We hypothesize that the packaging of methyl-CpG–DNA binding 
proteins (MBDs and MeCP2) and simultaneous translocation of histone Deacetylase (HDAC) to 
the hypermethylated segment of DNA is one of the mechanisms of remodeling/repression for 
hypermethylated genes by deacetylation of histones. 
 
2.3. The Methyl-binding Proteins: Linking DNA Methylation and 
Chromatin Structure:- 
 
 MBD proteins bind to methylated CpG islands and mediate transcriptional repression of 
affected genes. The MBD family of proteins consists of five members: MeCP2, MBD1, MBD2, 
MBD3 and MBD4 (Berger, et al., 2005). The correlation between DNA methylation and 
transcriptional inactivity is well established. However, a causative role for CpG methylation in 
repression of transcription has often been a subject for debate. Although many silenced genes are 
associated with dense CpG methylation, this epigenetic mark could be a downstream 
consequence of transcriptional inactivity rather than an active participant in the process of 
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repression. However, the identification of a family of proteins that bind to DNA containing 
methylated CpG dinucleotides established a causative link between CpG methylation and 
repression of transcription. Five MBD family members have now been identified. 
 
 
2.3.1. MBD1:-  
 MBD1 has an NH2-terminal MBD and a COOH-terminal TRD. In addition, full-length 
MBD1 contains three CXXC motifs similar to the motif present in Dnmt1. MBD1 binds 
preferentially to densely methylated DNA in vitro, and it represses transcription in a HDAC-
dependent manner in transfected cells (Cross, et al., 1997, Ng, H.et al., 2000, Fujita, et al., 2000). 
Consistent with its in vitro DNA binding characteristics, overexpressed green fluorescent 
protein-tagged MBD1 localizes to densely methylated major satellite DNA in mouse cells 
(Hendrich, et al.,1998), and it is concentrated at methylated pericentromeric regions of 
chromosome 1 in human cells (Fujita,et al.,1999). Endog- Cell Growth & Differentiation 
endogenous MBD1 is detected along Euchromatic regions in human diploid metaphase 
chromosome spreads, but it concentrates at centromeric heterochromatic regions of 
chromosomes 1, 9, 15, and 16, as well as regions of densely methylated spacer DNA sequences 
interspersed among rRNA genes. 
 
Furthermore, the intensity of MBD1 staining is generally inversely proportional to the 
staining intensity of acetylated histone H4 (66). In human cells, MBD1 mRNA is expressed as 
five alternatively spliced forms that encode isoforms differing in their COOH-terminal and 
CXXC regions. Although the functional consequences of these alternative forms are unclear, 
inclusion of all three CXXC motifs results in an MBD1 isoform capable of repressing 
transcription independently of DNA methylation in transfected cells. 
 
2.3.2. MBD2:- 
MBD2 exists as two differentially expressed isoforms (MBD2a/2b), of which MBD2a 
differs by a 152 AA N terminal extension (Hendrich and Bird, 1998). In several independent 
biochemical purifications of the MeCP1 complex, (Wade et al.,1999)MBD2 is proven to be a 
component of MeCP1 complex and is coupled with the Mi2/NuRD complex to mediate the gene 
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silencing effect of NuRD/MeCP1 complex directed to methylated genes (Zhang et al.,1999, Ng 
et al.,1999). MBD2 includes partially overlapping MBD and TRD domains (Boeke et al., 2000).  
 
Consistent with an HDAC-dependent model of gene repression, the TRD exhibits TSA-
sensitive transcription repression activity in reporter assays (Ng et al., 1999).The MBD binds to 
DNA with a single methylated CpG in vitro (Cross et al., 1997, Wade et al.,1999), and an 
MBD2-GFP fusion protein binds to major satellite DNA in transfected mouse cells (Cross et 
al.,1997). Furthermore, MBD2 has been reported to be associated with Sin3a (Boeke et al., 
2000). It is probable that the variation in reported factors and complexes associated with MBD2 
reflects several distinct yet overlapping cell context-reliant functions of this family of proteins. 
 
 
2.3.3. MBD3:- 
 MBD3 has extensive sequence similarity to MBD2 (Hendrich and Bird., 1998). It is 
expressed as several splice variants, some of which disrupt the MBD (Zhang et al., 1999). MBD3 
mRNA is expressed in the adult brain .In the developing brain, MBD3 expression can be 
detected in high levels in neuroepithelial cells whereasMBD2 is barely detected(Jung et 
al,2003).The protein has been identified as a component of the Mi-2/NuRD transcriptional co-
repressor complex that includes Mi-2 ATPase, HDAC, and other proteins (Wade et al,1999, 
Humphrey et al,2001). However, in vitro, mammalian MBD3 has little if any methyl-CpG-
binding activity, likely because of amino acid substitutions within the MBD (Hendrich et al, 
1998). MBD3 can be transiently induced by kindling or transient ischemia in rodent 
hippocampus, suggesting that these proteins may be involved in alteration of gene expression 
upon lesions (Francis et al, 2002, Jung et al., 2002).Therefore, unlike the case for the Xenopus 
orthologue of MBD3 which contains a MBD with methyl-CpG-binding activity it is unlikely that 
mammalian MBD3 plays a role in methylation dependent transcription repression.  
MBD3 is a necessary component for NuRD complex and involved in multiple gene 
regulatory pathways for embryogenesis (Hendrich et al., 2001). Future study using a strategy for 
brain-specific conditional knockout of MBD3 will shed light on the specific role of MBD3 in the 
nervous system. 
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2.3.4. MBD4:- 
 MBD4 includes a MBD similar to that of MeCP2, although the COOH-terminal domain 
is homologous to bacterial DNA repair enzymes (Hendrich et al, 1998). Although MBD4 is 
capable of binding to methyl-CpG sites, it has a higher affinity for 5mCpG-TpG mismatched 
sites (Hendrich et al., 1999), and the DNA repair domain provides DNA N-glycosylase activity 
at G-T mismatches (Hendrich et al., 1999, Petronzelli et al., 2000). Therefore, MBD4 is ideally 
suited to function in the repair of point mutations that result from spontaneous deamination of 5-
methylcytosine to thymine. In addition, MBD4 (also known as MED1) binds to the MLH1 DNA 
mismatch repair protein in vivo. Expression of a MBD4 mutant lacking the MBD induces 
microsatellite instability in cell lines, implicating MBD4 in this form of DNA repair as well 
(Bellacosa et al., 1999). These data suggest that MBD4 may serve as a strand discrimination 
factor for MLH1, directing mismatch repair activity to the newly synthesized strand. However, in 
an in vitro assay, nuclear extracts containing MBD4 perform mismatch repair independently of 
target CpG methylation status (Drummond, et al., 2001). 
                   
 MECP2 (methyl CpG binding protein 2 (Rett syndrome)) is a gene (Amir et al., 1999) 
that provides instructions for making its protein product, MECP2, also referred to as MeCP2 
(Lewis et al., 1992) MECP2 appears to be essential for the normal function of nerve cells. The 
protein seems to be particularly important for mature nerve cells, where it is present in high 
levels. The MeCP2 protein is likely to be involved in turning off ("repressing" or "silencing") 
several other genes. This prevents the genes from making proteins when they are not needed. 
Recent work has shown that MeCP2 can also activate other genes (Chahrour M, et al. 
2008).Within the brain, the MeCP2 protein is important for the function of nerve cells (neurons) 
and is present in high levels in mature neurons.  
 
This protein likely plays a role in maintaining connections (synapses) between neurons, 
where cell-to-cell communication occurs. Many of the genes that are known to be regulated by 
the MeCP2 protein play a role in normal brain function, particularly the maintenance of 
synapses. 
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Table 1: Genomic localizations of methyl-binding proteins in different species of mammals 
Species  MeCP2 MBD1  MBD2 MBD3  MBD4 Kaiso 
Homo 
sapiens   
 
 
Xq28 18q21 18q21 19p13.3 3q21–q22 Xq23 
Mus 
musculus 
XA7.3 18E2 18E2 10C1 6E3 XA3.3 
 
Rattus 
norvegicus 
Xq37 18q12.2 18q12.1 Not placed 4q42 Xq11 
Bos taurus X 24 Not placed 7 22 Not placed 
 
 
 
2.4. MBD Proteins act on Gene Silencing:- 
 The MBD sequence motif was defined by molecular analysis of prototype of MBD 
protein and MeCP2 (Nan et al., 1993). This MBD sequence motif was found to be both 
necessary and sufficient to be direct specific interaction with methyl-CpG-containing DNA 
fragments. It consists of approximately 70 amino acids and represents the sole sequence feature 
found in common all of the MBD family members. The single exception to this rule is case of 
the MBD2 and MBD3 which are nearly identical in amino acid sequences, and have common 
gene structures and are believed to have arisen from an ancient duplication in all the evolution of 
the vertebrate lineage (Hendrich et al., 2003). 
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Fig.3:  The figure shows the general structural domains of MeCP2 and the MBD family proteins. 
[MBD=methyl-CpG-binding domain; MeCP2=methyl-CpG-binding protein 2; TRD = 
transcriptional repression domain; CXXC = cysteine rich domain; GR=glycine and arginine 
repeats; E-repeat = glutamate repeat] (Dhasarathy and Wade, Journal of Biological essays, 
2008). 
  
The methylated fraction of this genome includes such interesting loci as imprinted genes 
and the transposable elements and inactive X chromosome, and their relics. These all regions are 
strongly repressed and DNA methylation is believed to be playing an integral role in 
establishment and/or maintenance of transcriptional repression. Interestingly, mammalian 
MBD3, unlike amphibian counterpart, fails to selectively recognize methylated DNA owing to 
substitution of a critical tyrosine residue within the MBD motif with phenylalanine (Fraga et al., 
2003). Four members of the MBD family are to be believed to function, at least in part, in 
transcriptional repression (Bird and Wolffe, 1999; Hendrich and Tweedie, 2003; Wade, 
2001).The fifth MBD protein, MBD4, has been DNA N-glycosylase enzymatic activity and 
probably functions in DNA repair (Hendrich et al., 1999). In most cases, all the MBD proteins 
are expressed ubiquitously (Hendrich and Bird, 1998; Meehan et al., 1992). 
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     Fig 4: Two potential models for gene regulation by MBD family members (Mehrnaz 
Fatemi and Paul A. Wade, Journal of cell science, 2006) 
A. In the specific interaction model, each methylated locus is associated with one and only 
one MBD family member. 
B. In the random interaction model, the association of a given methylated locus with an 
MBD family member is random 
 
2.4.1. Germline variants:- 
  
Three polymorphisms in MBD1 and Pro401Ala) have been investigated for their 
association with lung cancer risk (Jang et al., 2005). Further subgroup analyses suggested that all 
three polymorphisms are associated with an increased risk of lung adenocarcinoma. The three 
polymorphisms are in strong linkage disequilibrium, and in vitro analysis of the promoter 
activity of the variants of 634G.A and 501delT attributed much of the functional effect to lower 
MBD1 expression from the G allele of 634G.A.For MBD2 Zhu et al. (37) found a reduced risk 
of premenopausal breast cancer for the rare variants of two SNPs (rs1259938 and rs609791). No 
association was observed in postmenopausal women. (Cebrian et al., 2006) found no evidence of 
an association between SNPs or haplotypes in MBD2 and breast cancer risk in a similar 
population in a study that had more than 10 times the sample size of Zhu et al., but sub-group 
analyses by menopausal status were not reported. In MBD4, the Lys/Lys genotype was reported 
to increase the risk of esophageal squamous cell carcinoma by Hao et al., 2004). 
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2.4.2. Somatic changes:- 
 
 The role of somatic alterations in MBD proteins in cancer is unclear. It has been shown 
that MBD2 binds to the aberrantly methylated promoter of tumor suppressor genes (e.g. p14/ 
ARF and p16/Ink4A in colon cancer cell lines) and suppresses their expression (Magdinie et al., 
2001). Abnormalities in the expression level of MBD proteins in cancer cell lines, however, may 
be due to the increased cell proliferation in these cells (Sato et al., 2002). MECP2 over 
expression has also been observed in breast cancer and appears to be associated with estrogen 
receptor positivity (Muller et al., 2003). The study of Mbd2-deficient mice crossed on to an Apc 
Min/þ background has shown that these mice are resistant to the development of intestinal 
tumors and the dosage of Mbd2 is important for the tumor resistant effect (Sansom et al.,2003). 
 
 
2.5. Mechanisms of MeCP2-mediated gene silencing:- 
  
 MeCP2 protein binds methylated CpG sites at gene promoters and promotes gene 
silencing by associating with Sin3A and histone deacetylases to form co-repressor complexes 
and through its interaction with CREB selectively regulates active BDNF gene transcription 
(Akbarian & Huang, 2009; Chahrour et al., 2008; Chen et al., 2003; Klose & Bird, 2003; Nan et 
al., 1998). Rett syndrome is an X-linked neuron developmental disorder, which primarily affects 
females and leads to postnatal lethality 
in males (Amir et al., 1999). Patients with Rett syndrome suffer from severe motor and cognitive 
impairments and may often display autistic features. Rett syndrome is due to a mutation in the 
MeCP2 gene. Thus, MeCP2 mutation leads to abnormal regulation of genes necessary for proper 
development and cognitive function. Interestingly, recent work suggest that MeCP2 functions 
not only to repress gene transcription but to mediate activation of genes as well (Chahrour et al., 
2008 and see Fig. 3, Gupta et al., 2010) all in the context of memory formation. These studies 
provide us with new insights into the gene targets that could be deregulated due to loss of 
MeCP2 function in Rett syndrome. 
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    Fig 5: Mechanisms of MeCP2-mediated gene silencing and transcriptional activation.    
            (Farah D. Lubin, 2011) 
A. Generally, methyl-DNA binding domain (MBD) proteins such as MeCP2 are recruited to 
methylated CpG sites and assemble repressor enzymes to mediate repression of gene 
transcripts. 
B.  Although this is a well-characterized role of MBD proteins in transcriptional regulation, 
it has been reported that the MeCP2 MBD protein can also be associated with 
transcriptional activation via CREB1. 
 
 
 
2.6. Action of MBD proteins in cancer:- 
 
 It has recently been recognized that cancer is a manifestation of both abnormal genetic 
and epigenetic events (Jones, 2003). Deregulated epigenetic controls, which usually are 
represented by abnormal DNA methylation patterns such as global hypomethylation and region 
specific hypermethylation, are a hallmark of most cancers. Aberrant hypermethylation of 
promoter CpG islands and the resulting transcriptional silencing is nowadays a widely accepted 
mechanism of inactivation of tumor suppressor genes in cancer that actively contributes to 
tumorigenesis (Jones and Laird, 1999; Costello and Plass, 2001; Esteller, 2002; Herman and 
Baylin, 2003). Treatment of cancer cells with the demethylating agent 5-aza-2′-deoxycytidine 
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results in CpG island hypomethylation, MBD release, and gene re-expression, reinforcing the 
notion that association of MBDs with methylated promoters is methylation-dependent. Whereas 
several promoters are highly specific in recruiting a particular set of MBDs, other promoters 
seem to be less exclusive. The existence of these profiles provides a powerful set of markers for 
outlining the disruption of critical pathways in tumorigenesis and for deriving sensitive 
molecular detection strategies for virtually every human tumor type.  
 
          
Fig 6: Action of MBD Proteins and Tumorigenesis  
(Owen et al., Nature Clinical Practice Oncology (2007)) 
 
The systematic study of DNA methylation patterns in human cancer cell lines (Smiraglia 
et al.,2001,Paz et al.,2003) has shown that these are appropriate models for this type of study as 
they show methylation patterns that resemble their corresponding tumor types . The selectivity of 
MBDs for methylated DNA and their transcriptional repression properties suggest that they 
could exert their function in methylated promoters. The presence of MBD proteins in the 
methylated promoter of a gene in cancer was first shown in 2000, when Magdinier and Wolffe 
(Magdinier and Wolffe, 2001) identified MBD2 in the methylated promoter of p16
INK4a
 in colon 
cancer cells. Human MBD genes are considered housekeeping genes because they are widely 
expressed in somatic tissues. Given the epigenetic role of MBD proteins in regulating gene 
expression, MBDs may be involved in cancer development by affecting the expression of cancer 
related genes. In fact, there is growing evidence that aberrant expression of MBD proteins is 
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associated with human cancers (Patra et al., 2003, Schlegel et al., 2002). The MBD2 gene is 
mapped to the conserved region within human chromosome 18q21 (Hendrich et al., 1999).  
A recent finding also suggests that MBD2 has potential DNA demethylase activity 
(Bhattacharya et al., 1999), implying that it might mediate gene activation in addition to 
transcriptional repression. However, two subsequent studies could not demonstrate any 
demethylase activity of MBD2 (Ng et al., 1999, Wade et al., 1999), and this inconsistency in the 
functions of MBD2 remains to be resolved. So several studies in human cancer research have 
demonstrated that the MBD2 protein plays a role in tumorigenesis. Moreover, a significant 
reduction in MBD2 mRNA expression was found in human colorectal and gastric cancerous 
tissues (Kanai et al., 1999) and peripheral blood lymphocytes (Zhu et al., 2004) in bladder cancer 
patients, implying a protective role for MBD2 in tumorigenesis. MBD2 protein expression and 
its demethylase activity were detected in normal human prostate tissue but not in cancerous 
tissue (Patra et al., 2002). These differences between types of cancers in the abundance of MBD2 
levels may reflect different roles for MBD2 either in transcriptional repression or in the 
demethylation process. 
 
2.7. Epigenetic Signature Using MBD Proteins:- 
In cells and tissues, MeCP2 has been associated with gene silencing that appears to be local and 
mediated through recruitment of histone modification enzymes (W.G. Chen., et al, 2003, K. 
Martinowich, et al., 2003). However, some data indicate that the protein itself is not strongly 
associated with such activities in the mammalian brain (K. Hu, et al., 2006). There are reports of 
MeCP2-dependent higher-order chromatin structures associated with imprinted gene clusters 
(Horike et al., 2005) although these have also been questioned (Schule et al.,2007). In addition, 
MeCP2 has been implicated as an RNA binding protein involved in splicing of mRNA (Young et 
al., 2005). Finally, the question of where the protein is bound in vivo and what genes it associates 
with casts doubts on long-held models (Yasui, et al., 2007). The MBD protein family has been 
proposed as potential readers of the DNA methylation mark. Yet it is clear that the phenotypic 
consequences of mutation of the system for deposition of DNA methylation are far more 
profound than are the consequences of mutation of the MBD proteins themselves (Bird, 2006). 
The different members of the DNA methyltransferase family are essential in mammals; null 
mutants in MBD family members in mice are largely viable and fertile.
  
 
 
 
 
 
 
RATIONALE BEHIND THE PROJECT
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3. RATIONALE BEHIND THE PROJECT 
 
Proteins with a methyl-CpG-binding domain (MBD) can bind to single methylated CpGs 
and most of them are involved in transcription control. So far, five vertebrate MBD proteins have 
been described as MBD family members: MBD1, MBD2, MBD3, MBD4 and MECP2. 
 
Keeping this hypothesis in mind and based on the literature survey, the present work has 
been undertaken to investigate whether four methyl binding candidate proteins have putative 
transcriptional repression activity in vitro in cancerous tissue. 
 
The objectives of this project include:- 
 Comparative analysis of RNA isolation from three different RNA Purification 
techniques. 
 
 Comparative qualitative analysis of the expression level of Methyl Binding proteins – 
MBD1, MBD2, MBD3 and MBD4 in normal and leukemia Sample. 
  
 
 
 
MATERIALS AND METHODS
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4. MATERIALS AND METHODS 
 
4.1 Collection of Samples: 
        Blood was collected as the normal tissue from the local CWS Hospital, Rourkela, Odisha, 
stored in ice and immediately processed for better RNA extraction.  Cancer tissue (Lymph Node 
Carcinoma) was collected from National Medical College, Kolkata and stored in RNA later 
(Sigma) at –200C until the extraction of RNA. 
4.2 Extraction of Total RNA: 
Total RNA was extracted from blood (normal) and cancer tissue using GeneJET
TM 
RNA 
Purification Kit (Fermentas), Manual RNA Extraction techniques and Trizol method. 
4.2.1 Extraction from Blood By RNA Purification Kit:- 
The collected blood was centrifuged at 3000 rpm for 15 mins at 4° C. The supernatant 
containing the serum was separated from the pellet which contains the blood cells. The pellet 
was resuspended in 600 μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-
mercaptoethanol for every 1ml of Lysis Buffer) and vortexed to mix thoroughly. 450 μl of 
ethanol (96-100%) was mixed with the solution. About 700 μl of the lysate was transferred to a 
GeneJET
TM 
RNA Purification Column inserted in a collection tube and centrifuged at 12000 rpm 
for 1 min at 4° C. The flow-through was discarded and the column was placed into a new 2 ml 
RNase-free micro centrifuge tube. 700 μl of Wash Buffer 1(supplemented with 250 μl of ethanol 
for every 1ml Wash buffer 1) was added to the column and centrifuged for 1 min at 12000 rpm. 
The flow-through was discarded and 600 μl of Wash Buffer 2 (supplemented with 850 μl of 
ethanol for every 0.5 μl Wash buffer 2) was added to the column. It was centrifuged at 12000 
rpm for 1 min at 4° C. The flow-through was again discarded. Centrifugation was again done at 
12000 rpm for 1 min at 4 ° C by adding 250 μl of Wash buffer 2. The flow-through was 
discarded and the column was transferred to a sterile 1.5 RNase-free micro centrifuge tube. 100 
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μl of nuclease-free water was added to the column and centrifuged for 1 min at 12000 rpm to 
elute RNA. The RNA was stored at - 20° C for further use or immediately processed for cDNA 
synthesis. 
 
4.2.2. mRNA Extraction From Blood by Trizol RNA Extraction techniques:- 
The collected blood was transferred in a 2 ml tube with 1 ml Trizol. Then it was 
homogenized for 60 seconds in the polytron. 200μl of chloroform was added. Mixed by inverting 
the tube for 15 seconds. Incubated for 3 min at room temperature. Centrifuged at 12.000 g for 15 
minutes, Transferred the aqueous phase into a fresh Eppendorf tube.500μl of isopropanol was 
added. Centrifuged at maximum 12000 g for 10 minutes. Then the pellet was washed with 500μl 
70 % ethanol .Centrifuged at max. 7500 g for 5 min in the cold room .Dried the pellet on air for 
10 min .Dissolve the pellet in 50-100μl DEPC-H2O Incubated for 10 min at 60 0 C .Took 
spectrophotometer reading .And analyzed the RNA on a MOPS gel. Then 1-3μg RNA was 
dissolved in 11μl denaturation buffer. 1μl ethidium bromide (1mg/ml) was added and 
denaturated at 65 
0
C for 15 minutes. Then 1 % agarose gel was added in MOPS buffer plus 5 % 
formaldehyde. Then the gel was run at 40 V for 4 hour. 
  
4.3 Quantitative Estimation of RNA Concentration by Spectrophotometric 
Analysis: 
The concentration of the extracted total RNA from both blood and cancer tissue was 
quantified by measuring the absorbance at 260 nm in a spectrophotometer (ELICO, BL 200 Bio 
Spectrophotometer, double beam) and calculated by using the formula as given below: 
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
4.4 Quantitative Estimation of RNA Concentration by Denaturing Gel   
Electrophoresis: 
 
The extracted RNA from both blood and cancer tissue was run on a denaturing agarose 
gel and the quantity of RNA estimated from the band intensity. For denaturation gel (40 ml), 0.6 
g agarose (Sigma), 28.8 ml dH2O (Sigma), 7.2 ml formaldehyde (Sigma), 4 ml 10X MOPS 
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buffer were mixed properly. About 2 μl (2μg) of the total RNA was mixed with 18 μl 1X 
Reaction Buffer (2μl of 10X MOPS Buffer, 4 μl formaldehyde, 10 μl formamide (Sigma) ,2 μl 
0.2 mg/ml Etbr (Sigma)) and incubated at 55 °C for 1 hr. It was then cooled on ice and loaded in 
the wells of the denaturing gel. 
 
4.5. First strand cDNA synthesis: 
Total RNA (4 g) from both blood and cancer tissue were used for first strand cDNA 
synthesis by reverse transcription using RevertAid
TM 
First Strand cDNA Synthesis Kit 
(Fermentas) in a thermocycler (Biorad). The RNA were incubated with 1 l of oligo (dT)  
primers (100 μM, 0.2 μg/μl) and 12 μl of nuclease-free water at 65 C for 5 min. The reaction 
was cooled on ice to allow the primers to anneal to the RNA, then spin down and placed on ice 
again after which the following components were added to the reaction in order; 4 l of 5X 
Reaction Buffer, 1 l of RibolockTM RNase inhibitor (20 U/l), 2 l of 10 mM dNTPs and 1.0 
L of RevertAidTM M-MuLV-Reverse Transcriptase (200 U/l). The reagents were gently mixed 
and incubated for 1 hr at 42C. Heating at 70C for 5 min terminated the reaction and the 
synthesized cDNA was stored at –20 0 C for further use. 
4.6. Gene-specific PCR for amplification of the desired gene:- 
4.6.1 Selection of Primers: 
A set of specific forward and reverse primers for the amplification of the desired gene 
under study was selected from published papers (Patra et al., 2003; Zou et al., 2002). The cDNA 
of both the blood and cancer tissue synthesized were used as the template for the specific 
primers. The constitutively expressed housekeeping gene, β-actin was used as a positive control 
to ensure high quality. The primer sequences used for the PCR reaction are shown in Table 4: 
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Table 2: Table showing the sequence of the forward and backward primers. 
 
4.6.2 PCR conditions: 
 
The PCR sample mixtures, in a 25 μl volume, contained 17 μl of dH2O (Sigma), 2.5 μl of 1X 
PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, Sigma), 0.5 μl 
each of the forward and reverse primers (0.2 μM, Sigma) of MBD1, MBD2, MBD3, MBD4  and 
0.5 μl Taq DNA-polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was added. PCR 
amplifications of MBD1, MBD2, MBD3 and MBD4 were performed in a thermal cycler by 
initial denaturation at 94° C for 1 min, followed by 30 cycles of denaturation at 94° C for 20 
secs, annealing at 57 ° C for 20 secs, and extension at 72° C for 30 secs, followed by an final 
extension step at 72° C for 5 mins. For amplification of cDNA , the following conditions were 
followed: initial denaturation at 95° C for 5 mins, prior to 30 cycles of denaturation at 94° C for 
30 secs, annealing at 57 ° C for 20 secs, and extension at 72° C for 45 secs, followed by an final 
extension step at 72° C for 10 mins. 
 
 
PRIMER TYPE SEQUENCE 
 
MBD1 
Forward    5’ CACCCTCTTCGACTTCAAACAAG  3’ 
Reverse             5’ CAACCTGACGTTTCCGAGTCTT  3’ 
 
MBD2 
Forward 5’ AACCCTGCTGTTTGGCTTAAC  3’ 
Reverse 5’ CGTACTTGCTGTACTCGCTCTTC  3’ 
 
MBD3 
Forward  5’  CCGCTCTCCTTCAGTAAATGTAAC  3’ 
Reverse   5’ GGCTGGAGTTTGGTTTTCAGAA  3’ 
 
MBD4 
Forward   5’ TGGTGGTGCATGCCTGTAAT  3’ 
Reverse            5’ TGAGACAGGGTCTCTCTCTGTCAT  3’ 
 
β-ACTIN 
Forward             5’  TCTACAATGAGCTGCGTGTG  3’ 
Reverse 5’  TCTCCTTCTGCATCCTGTC  3’ 
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4.7 Agarose Gel Electrophoresis of the PCR products:- 
The generated PCR products were analyzed by electrophoresis on 1.5% agarose gel. 
Agarose gel was prepared with 1X TAE (Tris Acetate EDTA, Sigma) buffer. Before casting 
0.1% ethidium bromide was added to the gel. 15 μl of sample (PCR product) was loaded to each 
well along with 3 μl 1 X loading dye. 5 μl of DNA marker (1 kb, Sigma). The gel was run in 
TAE buffer at 100 volt for 40 minutes. 
4.8 Analysis of the Relative Expression level of the different genes:  
The relative levels of expression of each gene were analyzed by taking the absorbance 
through spectrophotometric readings. The ratios of desired genes/β-actin product were 
subsequently calculated after subtraction of the background pixel intensity for each gene of 
interest and used to assess the differences in expression levels between normal and leukemia 
sample. 
 
  
 
 
 
 
RESULT AND DISCUSSIONS 
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5. RESULTS AND DISCUSSION 
 
5.1 Quality Check of RNA Isolated from Normal And Cancer  Samples from 
three different RNA isolation methods:- 
The concentration of the extracted total RNA from normal tissue and leukemia sample 
was estimated by taking OD260nm/OD280nm, which was found to be 572 μg/ml for normal tissue 
and 409 μg/ml for leukemia sample  and then run on gel. Further integrity of the RNA samples 
was checked by RT-PCR using β-Actin primer pairs. Strong amplification products of β-Actin 
was found for all the genes in both normal and cancer tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7: The photograph of total RNA extracted from leukemia sample run in 1% agarose gel. 
    1           2           3            4 
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Fig 8:  The photograph of total RNA extracted from (A)  leukemia blood and (B) normal blood  
run in 1.5% denaturing gel. 
 
 
5.2 Gene Specific Amplification:- 
The PCR products obtained by gene specific amplification were run in a 1.5% agarose 
gel (Fig 9) and the concentration was estimated by spectrophotometric reading. The results 
obtained are given below. The expression of β-actin (682 bp) proves the integrity of the RNA 
extracted. 
The gene expression of MBD1, MBD2, MBD3, MBD4, in leukemia blood were 
analyzed. MBD1 is a transcriptional repressor characterized by two or three CXXC domains that 
bind methylated CpG islands of the tumor suppressors’ p16, VHL, and E-cadherin genes. MBD2 
has been reported to possess DNA (cytosine-5) demethylase activity along with repressor 
function. MBD4 is a repair enzyme of the DNA-glycosylase family and MBD3 apparently lacks 
specific methylated DNA-binding capability although it has a high degree of sequence similarity 
with MBD2. In the present study, the expression of MBD1, MBD2, MBD3 and GADD45 were 
seen, hence it can be said that while MBD1 (125 bp), MBD2 (101 bp), MBD3 (101 bp) were 
expressed in cancer tissue, MBD4 was not expressed. Expression of MBD2 might point towards 
a suspected demethylase activity by MBD2. 
 
 
LANE1   LANE2 LANE3   LANE4    1          2        3         4 
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Fig 9: The photograph of the different genes from leukemia sample after gene-specific 
amplification seen in a 1.5% agarose gel. 
On investigating the expression of other epigenetically modulating genes (fig 10) like HDAC, 
p300, it was compared with MBD group of proteins. 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10: The gel photograph showing the different genes from cancer tissue in different lanes, 1-
MBD1, 2-MBD2, 3-MBD3, 4-MBD4, 5-MARKER, 6-β-ACTIN,7-p300,8-HDAC. 
 
LANE  2 
LANE 2 - MBD2 
LANE 1 - MBD1 
LANE 3 - MBD3 
LANE 4 - MBD4 
LANE 5 - MARKER  
   (1.5 kb) 
LANE 6 - β-ACTIN 
LANE 1 LANE 3 
 
LANE 4 
 
LANE 5 
 
LANE 6 
 
1           2          3            4       5            6             7         8 
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5.3 Expression analysis of the desired genes:- 
After the gene-specific amplification of the given genes was done for both normal blood 
and leukemia sample, the concentration was checked by taking its OD260/280 in 
spectrophotometer. The following results were obtained (Table 2) and the data was plotted in the 
form of graph to do a comparative analysis of the expression level of the different genes.  
 
TABLE 3: The table shows the concentrations of PCR products after gene-specific amplification. 
 
Gene 
 
 
 
Concentration (μg/ml) at 
260/280 nm normal blood 
 
Concentration (μg/ml) at 
260/280 nm leukemia blood 
MBD1  
 
1.436                 1.786 
MBD2  1.064                 1.238 
MBD3  1.098  1.435 
MBD4  
 
1.176 1.584 
HDAC  
 
1.512 1.746 
P300  1.543 1.864 
β-actin  1.525 1.882 
 
 
The graphs were plotted (Fig 11,12) according to the data given above and the following 
results were obtained.MBD4 shows highest gene expression in comparison to 
MBD1,MBD2,MBD3 and the β-actin gene which is a constitutively expressed house-keeping 
gene which indicates that the leukemia sample shows increased demethylation activity. 
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Figure 11.Graph showing comparative study of expression level of the genes under study 
(MBD1, MBD2, MBD3, MBD4 and as well as β-actin in both normal & leukemia sample. 
 
 
 
  
 
  Figure 12. Graph showing comparative study of expression level of MBD proteins and HDAC, 
p300, as well as β-actin in both normal & leukemia sample.
  
 
 
 
CONCLUSION
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CONCLUSION 
In the present study, a comparative analysis of the expression of the different MBD 
proteins was studied in normal as well as cancer (leukemia) sample. We have observed, the 
expression of MBD1, MBD2, MBD3, hence it can be said that MBD1 (125 bp), MBD2 (101 bp), 
MBD3 (101 bp) might have some function in leukemia, whereas, MBD4 don’t have expression. 
Thus it can be concluded that MBD proteins expression have a cause in the leukemia. This 
indicates that they may be associated with DNA hypermethylation mediated gene silencing in 
cancer. Correlating the expression of MBD proteins with other epigenetic regulators such as 
HDAC, p300, it was seen that the expression of MBD1, MBD2 and MBD3 is comparable to 
HDAC. Thus, in the epigenetic context, DNA methylation and Histone deacetylation work in 
tandem to transcriptionally silence the genes in asscociation with the MBD group proteins. The 
expression of MBD2 is very low which substantiates the previous studies that report a suspected 
demethylase activity of MBD2. 
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